Ishikawa-ken, Japan

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)

PD, PK, and Safety of ALTO-203 in Patients With MDD

ENCALM: a Study of ENX-102 As a Monotherapy Treatment in Patients with Generalized Anxiety Disorder

Study of ALTO-300 in MDD

SUBLOCADE Long-term Outcomes

This is a Phase IV, prospective, multicentre, multinational, open-label, real-world observational study in participants with current or a history of OUD/opioid dependence.

Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

From Day 1 to Day 7, TM buprenorphine and randomized INDV-2000/Placebo will be administered, INDV-2000/Placebo will be administered alone from Day 8 onward. The randomized treatment period starts when the participant receives randomized treatment (at Day 1) and ends at his/her last study visit, if on INDV-2000/Placebo alone, or ends when starting buprenorphine rescue therapy.

International Multicentric Observational Study to Characterize Subpopulations of Patients With Autism Spectrum Disorder

A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)